• Publications
  • Influence
Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.
TLDR
In vivo biodistribution and tumor targeting characteristics of RG7116 are determined by means of immunoPET using 89Zr-RG7116 and tracer uptake in organs of interest and tumor lesions was quantified as standardized uptake value (SUV) and tumor-to-background ratios (TBR).
Abstract A85: Preclinical evaluation of the radiolabeled bispecific T-cell engager 89Zr-AMG 211 targeting CEA-positive tumors
TLDR
This study showed dose-dependent CEA-specific targeting of 89Zr-AMG 211 in LS174T bearing mice with the highest uptake 3 h after injection and a prolonged imageable tumor retention up to 48 h, and showed similar CEA binding as unlabeled AMG 211.
Abstract 5307: VEGF downregulation by HSP90 inhibitor NVP-AUY922 visualized with89Zr-bevacizumab PET in triple negative breast cancer (TNBC)
TLDR
NPV-AUY922 downregulates VEGF in a TNBC mouse model, and can therefore potentially serve as biomarker for early HSP90 inhibition effect in TNBC.
Imaging human pancreatic tumor xenografts with 89Zr-labeled anti-mesothelin antibody
TLDR
89Zr-AMA tumor uptake is antigen-specific in MSLN-expressing tumors and can be translated to the clinic for serial non-invasive PET imaging.
89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.
TLDR
A PET imaging study with 89Zr-lumretuzumab was performed to demonstrate tumor targeting and support dose selection by evaluating the dose required for target saturation in patients with HER3-positive solid tumors.
...
1
2
3
4
...